C4 Therapeutics, Inc.
NASDAQ:CCCC
6.06 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 20.756 | 31.096 | 45.785 | 33.195 | 21.381 | 19.364 |
| Cost of Revenue
| 7.737 | 7.572 | 2.907 | 77.468 | 47.664 | 28.592 |
| Gross Profit
| 13.019 | 23.524 | 42.878 | -44.273 | -26.283 | -9.228 |
| Gross Profit Ratio
| 0.627 | 0.756 | 0.937 | -1.334 | -1.229 | -0.477 |
| Reseach & Development Expenses
| 117.706 | 117.841 | 94.665 | 78.44 | 48.059 | 28.592 |
| General & Administrative Expenses
| 42.081 | 42.789 | 33.254 | 15.204 | 8.774 | 7.161 |
| Selling & Marketing Expenses
| -7.737 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 34.344 | 42.789 | 33.254 | 15.204 | 8.774 | 7.161 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0.325 | -0.007 |
| Operating Expenses
| 152.05 | 160.63 | 127.919 | 93.644 | 56.833 | 35.753 |
| Operating Income
| -139.031 | -129.534 | -82.134 | -60.449 | -35.452 | -16.389 |
| Operating Income Ratio
| -6.698 | -4.166 | -1.794 | -1.821 | -1.658 | -0.846 |
| Total Other Income Expenses Net
| 7.818 | 1.359 | -1.758 | -6.512 | 2.157 | -0.007 |
| Income Before Tax
| -131.213 | -128.175 | -83.892 | -66.961 | -33.295 | -15.711 |
| Income Before Tax Ratio
| -6.322 | -4.122 | -1.832 | -2.017 | -1.557 | -0.811 |
| Income Tax Expense
| 1.28 | -1.676 | 2.145 | -0.626 | 0.804 | 0.678 |
| Net Income
| -132.493 | -126.499 | -86.037 | -66.335 | -34.099 | -15.711 |
| Net Income Ratio
| -6.383 | -4.068 | -1.879 | -1.998 | -1.595 | -0.811 |
| EPS
| -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
| EPS Diluted
| -2.67 | -2.59 | -1.87 | -1.54 | -0.79 | -1.06 |
| EBITDA
| -131.294 | -125.959 | -80.255 | -58.439 | -33.857 | -15.116 |
| EBITDA Ratio
| -6.326 | -4.051 | -1.753 | -1.76 | -1.584 | -0.781 |